The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases
Open accessAbstract
In the preantibiotic era, passive antibody administration (serum therapy) was useful for the treatment of many infectious diseases. The introduction of antimicrobial chemotherapy in the 1940s led to the rapid abandonment of many forms of passive antibody therapy. Chemotherapy was more effective and less toxic than antibody therapy. In this last decade of the 20th century the efficacy of antimicrobial chemotherapy is diminishing because of the rapidly escalating number of immunocompromised individuals, the emergence of new pathogens, the reemergence of old pathogens, and widespread development of resistance to antimicrobial drugs. This diminishment in the effectiveness of chemotherapy has been paralleled by advances in monoclonal antibody technology that have made feasible the generation of human antibodies. This combination of factors makes passive antibody therapy an option worthy of serious consideration. We propose that for every pathogen there exists an antibody that will modify the infection to the benefit of the host. Such antibodies are potential antimicrobial agents. Antibody-based therapies have significant advantages and disadvantages relative to standard chemotherapy. The reintroduction of antibody-based therapy would require major changes in the practices of infectious disease specialists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a Mutant Escherichia coli
Ziegler, E. J., McCutchan, J. A., Fierer, J., Glauser, M. P., Sadoff, J. C., Douglas, H., & Braude, A. I. (1982) · New England Journal of Medicine · doi:10.1056/nejm198211113072001 · Cited by 1,046
Greenman, R. L. (1991) · JAMA · doi:10.1001/jama.266.8.1097 · Cited by 752
Waldmann, T. A., & Strober, W. (2015) · Chemical Immunology and Allergy · doi:10.1159/000385919 · Cited by 723
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
Hale, G., Clark, M. R., Marcus, R., Winter, G., Dyer, M. J. S., Phillips, J. M., Riechmann, L., & Waldmann, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90588-0 · Cited by 688
Reed, E. C., Bowden, R. A., Dandliker, P. S., Lilleby, K. E., & Meyers, J. D. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-10-783 · Cited by 548
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., & Khazaeli, M. B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4220 · Cited by 524
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., & Morgan, A. C. (1985) · PubMed · Cited by 488
Frickhofen, N., Abkowitz, J. L., Safford, M., Berry, J. M., Antunez-de-Mayolo, J., Astrow, A., Cohen, R., Halperin, I., King, L., Mintzer, D., et al. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-12-926 · Cited by 471
Intracellular neutralization of virus by immunoglobulin A antibodies.
Mazanec, M. B., Kaetzel, C. S., Lamm, M. E., Fletcher, D., & Nedrud, J. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.6901 · Cited by 440
Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.
Friden, P. M., Walus, L. R., Musso, G. F., Taylor, M. A., Malfroy, B., & Starzyk, R. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4771 · Cited by 402
Humanised monoclonal antibody therapy for rheumatoid arthritis
Isaacs, J. D., Hale, G., Cobbold, S. P., Waldmann, H., Watts, R. A., Hazleman, B. L., & Keogan, M. T. (1992) · The Lancet · doi:10.1016/0140-6736(92)92294-p · Cited by 308
Smith, T. W., Butler, V. P., Haber, E., Fozzard, H., Marcus, F. I., Bremner, W. F., Schulman, I. C., & Phillips, A. (1982) · New England Journal of Medicine · doi:10.1056/nejm198211253072201 · Cited by 296
Persistent and Fatal Central-Nervous-System ECHOvirus Infections in Patients with Agammaglobulinemia
Wilfert, C. M., Buckley, R. H., Mohanakumar, T., Griffith, J. F., Katz, S. L., Whisnant, J. K., Eggleston, P. A., Moore, M., Treadwell, E., Oxman, M. N., et al. (1977) · New England Journal of Medicine · doi:10.1056/nejm197706302962601 · Cited by 286
Protective murine monoclonal antibodies to Cryptococcus neoformans
Mukherjee, J., Scharff, M. D., & Casadevall, A. (1992) · Infection and Immunity · doi:10.1128/iai.60.11.4534-4541.1992 · Cited by 282
Self-citationDalakas, M. C. (1994) · Neurology · doi:10.1212/wnl.44.2.223 · Cited by 274
Serum therapy revisited: animal models of infection and development of passive antibody therapy
Casadevall, A., & Scharff, M. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1695 · Cited by 251
Self-citationIntravenous Immunoglobulin Therapy for Toxic Shock Syndrome
Barry, W. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480240077038 · Cited by 248
Dromer, F., Charreire, J., Contrepois, A., Carbon, C., & Yeni, P. (1987) · Infection and Immunity · doi:10.1128/iai.55.3.749-752.1987 · Cited by 243 · cited 1×
“However, administration of preformed antibodies can modify the course of cryptococcal infection in various animal models [132] [133] [134] [135] [136] , and the combination of antibody and amphotericin B is a more effective treatment than the use of either agent alone [137] [138] [139] .”
BackgroundAnti-Endotoxin Monoclonal Antibodies
Warren, H. S., Danner, R. L., & Munford, R. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261711 · Cited by 226
Triguero, D., Buciak, J. B., Yang, J., & Pardridge, W. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4761 · Cited by 210
Immune Enhancement of Viral Infection
Halstead, S. B. (2015) · Chemical Immunology and Allergy · doi:10.1159/000406537 · Cited by 206
Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia
Weeks, J. C., Tierney, M. R., & Weinstein, M. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107113250202 · Cited by 204
Talkington, D. F., Schwartz, B., Black, C. M., Todd, J. K., Elliott, J., Breiman, R. F., & Facklam, R. R. (1993) · Infection and Immunity · doi:10.1128/iai.61.8.3369-3374.1993 · Cited by 195
Mukherjee, J., Nussbaum, G., Scharff, M. D., & Casadevall, A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.405 · Cited by 182
Self-citationBarbas, C. F., Crowe, J. E., Cababa, D., Jones, T. M., Zebedee, S. L., Murphy, B. R., Chanock, R. M., & Burton, D. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10164 · Cited by 177
THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS
Flexner, S. (1913) · Journal of Experimental Medicine · doi:10.1084/jem.17.5.553 · Cited by 176
Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization.
Sădziene, A., Rosa, P. A., Thompson, P. A., Hogan, D. M., & Barbour, A. G. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.3.799 · Cited by 162
Intravenous Immune Globulin for the Prevention of Nosocomial Infection in Low-Birth-Weight Neonates
Baker, C. J., Melish, M. E., Hall, R. T., Casto, D. T., Vasan, U., & Givner, L. B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207233270401 · Cited by 156
The Intravenous Immunoglobulin Collaborative Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199207233270404 · Cited by 155
Cameron, M. L., Schell, W. A., Bruch, S., Bartlett, J. A., Waskin, H. A., & Perfect, J. R. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2449 · Cited by 152
A Brief History of the Pneumococcus in Biomedical Research: A Panoply of Scientific Discovery
WATSON, D. A., Musher, D. M., Jacobson, J. W., et al. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.5.913 · Cited by 152
Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis.
Matthews, R., Burnie, J., Howat, D. W., Rowland, T., & Walton, F. (1991) · PubMed Central · Cited by 148
A RANDOMISED TRIAL OF ORAL GAMMAGLOBULIN IN LOW-BIRTH-WEIGHT INFANTS INFECTED WITH ROTAVIRUS
BARNES, G. L., Hewson, P. H., Mclellan, J. A., Doyle, L. W., Knoches, A. M. L., & Kitchen, W. H. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92496-5 · Cited by 146
Sanford, J., Lupan, D. M., Schlageter, A. M., & Kozel, T. R. (1990) · Infection and Immunity · doi:10.1128/iai.58.6.1919-1923.1990 · Cited by 145
Mukherjee, J., Zuckier, L. S., Scharff, M. D., & Casadevall, A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.580 · Cited by 136
Self-citationDromer, F., Salamero, J., Contrepois, A., Carbon, C., & Yeni, P. (1987) · Infection and Immunity · doi:10.1128/iai.55.3.742-748.1987 · Cited by 128
Intravenous Immunoglobulins as Therapeutic Agents
Stiehm, E. R., ASHIDA, E., KIM, K. S., WINSTON, D. J., HAAS, A., & GALE, R. P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-367 · Cited by 105
Halter, R., Pohlner, J., & Meyer, T. F. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08415.x · Cited by 102
A BIOLOGIC CLASSIFICATION OF PNEUMOCOCCI BY MEANS OF IMMUNITY REACTIONS
Dochez, A. R. (1913) · JAMA · doi:10.1001/jama.1913.04350100005003 · Cited by 95
Dromer, F., & Charreire, J. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/163.5.1114 · Cited by 92
Roles of antibodies and complement in phagocytic killing of enterococci
Arduino, R. C., Murray, B. E., & Rakita, R. M. (1994) · Infection and Immunity · doi:10.1128/iai.62.3.987-993.1994 · Cited by 88
Finland, M., Brown, J. W., & Rauh, A. E. (1938) · New England Journal of Medicine · doi:10.1056/nejm193806232182501 · Cited by 76
Monoclonal Antibodies for treatment of Gram-Negative Infections
Young, L. S., Gascon, R. L., Alam, S., & Bermudez, L. E. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.supplement_7.s1564 · Cited by 76
Immunologic and pharmacologic concepts of monoclonal antibodies
Zuckier, L. S., Rodriguez, L. D., & Scharff, M. D. (1989) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(89)80012-1 · Cited by 72
Self-citationPassive Immunization Against Cryptococcus neoformans.
Gadebusch, H. H. (1958) · Experimental Biology and Medicine · doi:10.3181/00379727-98-24123 · Cited by 62
Acute renal failure after intravenous immunoglobulin therapy.
Pasatiempo, A. M. G., Kroser, J. A., Rudnick, M. R., & Hoffman, B. I. (1994) · PubMed · Cited by 60
CONVALESCENT WHOLE BLOOD, PLASMA AND SERUM IN PROPHYLAXIS OF MEASLES
Zingher, A. (1924) · JAMA · doi:10.1001/jama.1924.02650410022011 · Cited by 60
The clinical value of antilymphocyte antibodies.
Cosimi, A. B. (1981) · PubMed · Cited by 56
Prophylaxis of Primary Cytomegalovirus Disease in Renal Transplant Recipients
Conti, D. J. (1994) · Archives of Surgery · doi:10.1001/archsurg.1994.01420280121016 · Cited by 55
The Efficacy of Combination Immunotherapy in Experimental Pseudomonas Sepsis
Cross, A. S., Opal, S. M., Palardy, J., et al. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.1.112 · Cited by 55
Fisher, M. W. (1957) · PubMed · Cited by 55
Hemophilus influenzae(Pfeiffer Bacillus) Meningitis and Its Specific Treatment
FOTHERGILL, L. R. D. (1937) · New England Journal of Medicine · doi:10.1056/nejm193704082161401 · Cited by 52
Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients
Harkonen, S., Scannon, P. J., Mischak, R. P., S̄pitler, L. E., Foxall, C., Kennedy, D., & Greenberg, R. N. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.5.710 · Cited by 51
Emerging Antimicrobial Resistance and the Immunocompromised Host
Shlaes, D. M., Binczewski, B., & Rice, L. B. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.supplement_2.s527 · Cited by 51
Chronic ECHO type 5 virus meningoencephalitis in X‐linked hypogammaglobulinemia
Bodensteiner, J. B., Morris, H. H., Howell, J. T., et al. (1979) · Neurology · doi:10.1212/wnl.29.6.815 · Cited by 50
Passive immunization in murine cryptococcosis
Graybill, J. R., Hague, M., & Drutz, D. J. (1981) · Medical Mycology · doi:10.1080/00362178185380411 · Cited by 50
The treatment of bacterial infections with the combination of antibiotics and gamma globulin.
WAISBREN, B. A. (1957) · PubMed · Cited by 49
Placental transfer of human IgG subclasses.
Virella, G., Nunes, S., & Tamagnini, G. (1972) · PubMed Central · Cited by 48
Serum Protein Enhancement of Antibiotic Therapy in Cryptococcosis
Gordon, M. A., & Lapa, E. W. (1964) · The Journal of Infectious Diseases · doi:10.1093/infdis/114.4.373 · Cited by 47
THE RELIABILITY OF SPUTUM TYPING AND ITS RELATION TO SERUM THERAPY
Bullowa, J. G. M. (1935) · JAMA · doi:10.1001/jama.1935.02760450032007 · Cited by 47
History of Opportunistic Infection in the Immunocompromised Host
Armstrong, D. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.supplement_2.s318 · Cited by 45
TREATMENT OF HAEMOPHILUS INFLUENZAE INFECTIONS AND OF MENINGOCOCCIC AND PNEUMOCOCCIC MENINGITIS
Alexander, H. E. (1943) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1943.02010200074010 · Cited by 44
Passive immunization for the prevention and treatment of HIV infection
Zolla‐Pazner, S., & Górny, M. K. (1992) · AIDS · doi:10.1097/00002030-199211000-00001 · Cited by 43
Lazarovits, A. I., Rochon, J., Banks, L., Hollomby, D. J., Muirhead, N., Jevnikar, A. M., White, M. J., Amlot, P. L., Beauregard-Zollinger, L., & STILLER, C. R. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.11.5163 · Cited by 43
Oishi, K., Sonoda, F., Iwagaki, A., et al. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.164 · Cited by 35
Clayton, A. (1977) · Europe PMC (PubMed Central) · Cited by 33
The Units of Protective Antibody in Anti-Pneumococcus Serum and Antibody Solution
Felton, L. D. (1928) · The Journal of Infectious Diseases · doi:10.1093/infdis/43.6.531 · Cited by 33
THE MENINGOCOCCUS (NEISSERIA INTRACELLULARIS)
Branham, S. E. (1940) · Bacteriological Reviews · doi:10.1128/br.4.2.59-96.1940 · Cited by 29
Human Immunoglobulins for intravenous use and hepatitis C viral transmission
Slade, H. B. (1994) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.1.6.613-619.1994 · Cited by 29
SERUM AND SULPHANILAMIDE IN ACUTE MENINGOCOCCAL MENINGITIS
Banks, H. (1938) · The Lancet · doi:10.1016/s0140-6736(00)87994-5 · Cited by 29
Therapy with antibody to tumor necrosis factor in sepsis
Pennington, J. E. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.supplement_2.s515 · Cited by 26 · cited 1×
“Recent attempts to develop antibody therapy for gram-negative sepsis have focused on mAbs to neutralize endotoxin [123, 157, 158] and cytokines [159] .”
BackgroundINTRAVENOUS TREATMENT OF MENINGOCOCCIC MENINGITIS WITH MENINGOCOCCUS ANTITOXIN
Hoyne, A. L. (1936) · JAMA · doi:10.1001/jama.1936.02770330008003 · Cited by 26
Erlich, K. S., Dix, R. D., & MILLS, J. S. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1006 · Cited by 17
Serums, Antitoxin, and Drugs in the Treatment of Meningococcus Meningitis
Branham, S. E. (1938) · Public Health Reports (1896-1970) · doi:10.2307/4582519 · Cited by 10
Protection of Mice against Meningococcus Infection by Polyvalent Antimeningococcic Serum
Branham, S. E. (1935) · Public Health Reports (1896-1970) · doi:10.2307/4581558 · Cited by 4
Cited by
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903
Self-citationDeployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Self-citationMascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4009-4018.1999 · Cited by 783
Passive antibody therapy for infectious diseases
Casadevall, A., Dadachova, E., & Pirofski, L.-A. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro974 · Cited by 531
Self-citationConvalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Joyner, M. J., Carter, R. E., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031893 · Cited by 509
Self-citation
Metadata
- Authors
- Casadevall, A., & Scharff, M. D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-07-01
- Volume
- 21
- Issue
- 1
- Pages
- 150-161
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2074305256
- Cited by
- 318
- References
- 77
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.